다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Cell, v.159 no.1, 2014년, pp.176 - 187
Gao, D. , Vela, I. , Sboner, A. , Iaquinta, Phillip J. , Karthaus, Wouter R. , Gopalan, A. , Dowling, C. , Wanjala, Jackline N. , Undvall, Eva A. , Arora, Vivek K. , Wongvipat, J. , Kossai, M. , Ramazanoglu, S. , Barboza, Luendreo P. , Di, W. , Cao, Z. , Zhang, Q. , Sirota, I. , Ran, L. , MacDonald, Theresa Y. , Beltran, H. , Mosquera, J.M. , Touijer, Karim A. , Scardino, Peter T. , Laudone, Vincent P. , Curtis, Kristen R. , Rathkopf, Dana E. , Morris, Michael J. , Danila, Daniel C. , Slovin, Susan F. , Solomon, Stephen B. , Eastham, James A. , Chi, P. , Carver, B. , Rubin, Mark A. , Scher, Howard I. , Clevers, H. , Sawyers, Charles L. , Chen, Y.
AI-Helper
The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate cancer has hampered progress in understanding disease pathogenesis and therapy response. Using a 3D organoid system, we report success in long-term culture of prostate cancer from biopsy specimens and circu...
Cell Arora 155 1309 2013 10.1016/j.cell.2013.11.012 Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade
Cell Baca 153 666 2013 10.1016/j.cell.2013.03.021 Punctuated evolution of prostate cancer genomes
eLife Balbas 2 e00499 2013 10.7554/eLife.00499 Overcoming mutation-based resistance to antiandrogens with rational drug design
Nat. Genet. Barbieri 44 685 2012 10.1038/ng.2279 Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Cell Stem Cell Barker 6 25 2010 10.1016/j.stem.2009.11.013 Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro
Nature Barretina 483 603 2012 10.1038/nature11003 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Cancer Discov Beltran 1 487 2011 10.1158/2159-8290.CD-11-0130 Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets
Cancer Res. Burkhardt 73 2795 2013 10.1158/0008-5472.CAN-12-1342 CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer
Nature 474 609 2011 10.1038/nature10166 Integrated genomic analyses of ovarian carcinoma
Cancer Cell Carver 19 575 2011 10.1016/j.ccr.2011.04.008 Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
Cancer Discov. Cerami 2 401 2012 10.1158/2159-8290.CD-12-0095 The cBiol. cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
Nat. Med. Chen 19 1023 2013 10.1038/nm.3216 ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
N. Engl. J. Med. de Bono 364 1995 2011 10.1056/NEJMoa1014618 Abiraterone and increased survival in metastatic prostate cancer
Genes Chromosomes Cancer Demichelis 48 366 2009 10.1002/gcc.20647 Distinct genomic aberrations associated with ERG rearranged prostate cancer
Bioinformatics Dobin 29 15 2013 10.1093/bioinformatics/bts635 STAR: ultrafast universal RNA-seq aligner
Nat. Med. Druker 2 561 1996 10.1038/nm0596-561 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Nature Garnett 483 570 2012 10.1038/nature11005 Systematic identification of genomic markers of drug sensitivity in cancer cells
Nature Grasso 487 239 2012 10.1038/nature11125 The mutational landscape of lethal castration-resistant prostate cancer
Cancer Res. Horoszewicz 43 1809 1983 LNCaP model of human prostatic carcinoma
EMBO J. Huch 32 2708 2013 10.1038/emboj.2013.204 Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis
Nature Huch 494 247 2013 10.1038/nature11826 In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
Hum. Pathol. Johnson 44 2241 2013 10.1016/j.humpath.2013.05.006 ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma
Natl. Cancer Inst. Monogr. Kaighn 49 17 1978 Prostate carcinoma: tissue culture cell lines
Cell Karthaus 158 2014 Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures
In Vivo Korenchuk 15 163 2001 VCaP, a cell-based model system of human prostate cancer
J. Pathol. Krohn 231 130 2013 10.1002/path.4223 Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers
Proc. Natl. Acad. Sci. USA Kumar 108 17087 2011 10.1073/pnas.1108745108 Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers
Bioinformatics Li 26 589 2010 10.1093/bioinformatics/btp698 Fast and accurate long-read alignment with Burrows-Wheeler transform
Oncogene Liu 31 3939 2012 10.1038/onc.2011.554 Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer
Am. J. Pathol. Liu 180 599 2012 10.1016/j.ajpath.2011.10.036 ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells
Genome Res. McKenna 20 1297 2010 10.1101/gr.107524.110 The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data
Neoplasia Mertz 9 200 2007 10.1593/neo.07103 Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model
Clin. Cancer Res. Navone 3 2493 1997 Establishment of two human prostate cancer cell lines derived from a single bone metastasis
Am. J. Surg. Pathol. Parwani 28 651 2004 10.1097/00000478-200405000-00014 Prostate carcinoma with squamous differentiation: an analysis of 33 cases
Cancer J. Rathkopf 19 43 2013 10.1097/PPO.0b013e318282635a Androgen receptor antagonists in castration-resistant prostate cancer
Genome Biol. Roberts 12 R22 2011 10.1186/gb-2011-12-3-r22 Improving RNA-Seq expression estimates by correcting for fragment bias
ASCO Meeting Abstracts Ryan 30 LBA4518 2012 Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Nature Sato 459 262 2009 10.1038/nature07935 Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Hum. Pathol. Schelling 44 2227 2013 10.1016/j.humpath.2013.05.005 Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry
N. Engl. J. Med. Scher 367 1187 2012 10.1056/NEJMoa1207506 Increased survival with enzalutamide in prostate cancer after chemotherapy
J. Clin. Invest. Sharma 120 4478 2010 10.1172/JCI44239 The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
J. Clin. Oncol. Smaletz 20 3972 2002 10.1200/JCO.2002.11.021 Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
Nature Solit 439 358 2006 10.1038/nature04304 BRAF mutation predicts sensitivity to MEK inhibition
In Vitro Cell. Dev. Biol. Anim. Sramkoski 35 403 1999 10.1007/s11626-999-0115-4 A new human prostate carcinoma cell line, 22Rv1
Cancer Cell Taylor 18 11 2010 10.1016/j.ccr.2010.05.026 Integrative genomic profiling of human prostate cancer
Lancet Thatcher 366 1527 2005 10.1016/S0140-6736(05)67625-8 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Cancer Cell Tomlins 13 519 2008 10.1016/j.ccr.2008.04.016 The role of SPINK1 in ETS rearrangement-negative prostate cancers
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.